
Pocket Program

*Current as of Thursday, October 13, 2011. Schedule subject to change.
Please see final daily schedules posted in the corridors.*

Sponsors	3
Advisory Committee	4
Chronological Listing of Events	5
Alphabetical Listing of Presenting Companies	16
Categorical Listing of Presenting Companies.....	19
Hotel Maps.....	23
Upcoming BIO Events	24

A Decade of Excellence

THE 10TH ANNUAL

Bio ***Investor Forum***



BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading innovator and partnering meetings held around the world.

Published by

Biotechnology Industry Organization
1201 Maryland Ave., SW, Suite 900
Washington, DC 20024
202-962-9200
www.bio.org

Any portion of this material may be reproduced with attribution to BIO © 2011 by the Biotechnology Industry Organization.

Biotechnology Industry Organization

James C. Greenwood, President and Chief Executive Officer

Emerging Companies and Business Development

Alan F. Eisenberg, Executive VP, Emerging Companies & Business Development

John Craighead, PhD, Managing Director, Investor Relations & Business Development

Jen Welch, CMP, Director, Meetings & Operations

Wesley Triplett, Director, Business Development Marketing

Robyn Song, Director, Event & Services Marketing, Business Development Department

David Thomas, Director, Industry Research & Analysis

Tamy Dalal, Senior Manager, Strategic Alliances & Business Development

Bernadette Blake, Manager, Registration & Customer Service

Joe Colangelo, Senior Manager, Business Development

Celia Economides, MPH, Manager, Investor Relations

Rena'e Love, Manager, Partnering Programs & Investor Outreach

Sponsorship and Membership

Amy Finan, Vice President, Corporate Development & Marketing

Jason Rupp, Managing Director, Membership

John Sloan, Managing Director, External Relations & Development

Susanna Ling, Director, Sponsorship

Beth Perkins, Senior Manager, Sponsorship

Elizabeth Gaskins, Manager, Membership

Privacy

In accordance with its Privacy Policy, BIO does not sell or rent its customer information or usage data to third parties.

Sponsors

LOCAL CO-HOST SPONSOR

BayBio

SUPPORTING BANK SPONSORS

BMO Capital Markets ROTH Capital Partners
Rodman & Renshaw, LLC

BIO DOUBLE HELIX SPONSORS

Abbott
Amgen
Eli Lilly and Company
Janssen Pharmaceutical Companies of
Johnson & Johnson
Merck

BIO HELIX SPONSOR

GlaxoSmithKline

CONFERENCE SPONSORS

BioMedTracker Dawson James Securities
BIOTECanada Knobbe Martens Olson & Bear LLP
Business Wire VWR International
Campbell Alliance

Advisory Committee

John Chambers

Managing Director & Head of Healthcare Investment Banking
ROTH Capital Partners

Annette Grimaldi

Managing Director
BMO Capital Markets

James I. Healy, MD, PhD

General Partner
Sofinnova Ventures, LLC

Adam Koppel, MD, PhD

Managing Director
Brookside Capital, LLC

Ronald W. Lennox, DPhil

Founder
CHL Medical Partners, LLC

Gail Maderis

President & CEO
BayBio

Gwen A. Melincoff

Senior Vice President
Business Development, Strategic Investment Group
Shire Pharmaceuticals, Inc.

Jeffrey M. Ostrove, PhD

President & Chief Executive Officer
Ceregene Inc.

Andrew J. Schwab

Founder & Managing Partner
5AM Ventures, LLC

Katya Smirnyagina, PhD

Venture Partner
Alta Partners, LLC

Samuel Wu, MD, PhD

Managing Director
MedImmune Ventures

Asish K. Xavier, PhD

Vice President
Johnson & Johnson Development Corporation

Chronological Listing of Events

*Current as of Thursday, October 13, 2011. Schedule subject to change.
Please see final daily schedules posted in the corridors.*

*Discovery Track company presentations are 15 minutes long,
including a Q&A session in the same room.*

*Public and private company presentations are 20 minutes long
and will be followed by a 5-minute Q&A session in the same room.*

A Decade of Excellence

THE 10TH ANNUAL

Bio ***Investor Forum***

Monday, October 24

1:00 PM–6:30 PM

BIO TECHNOLOGY TRANSFER SYMPOSIUM

Twin Peaks North/South

Commercialization and Job Creation: What Does it Really Take?

SPONSORED BY: Schwegman, Lundberg, and Woessner

In the midst of turbulent economic times, and at a moment when the U.S. is looking to encourage technology job creation in the coming decade, an increasing number of public and private sector initiatives have been proposed to spur job creation. While the U.S. leads in the area of biotechnology, there is no guarantee that this competitive edge will continue. Moreover, although the U.S. is more prolific in life science discoveries than any other single country in the world, there is a sense that many of these discoveries do not make it to the market place. Experts believe that it is through commercialization of these early stage discoveries, that the U.S. will be able to jump-start job creation.

This public policy focused forum will explore proposals and initiatives intended to do this through the lens of a biotechnology innovator/entrepreneur. This leadership forum will explore the policies and initiatives that are necessary to position more university innovations for effective partnering and commercialization. Leaders in state, federal and regional governments, academia, industry and non-profit philanthropic organizations will discuss how they propose to translate early-stage discoveries into jobs, products and ultimately economic growth for their region.

Monday, October 24

2:00 PM–6:00 PM

Speaker Ready-Room Open

Mendocino

Tuesday, October 25

7:00 AM–6:00 PM	Registration Open	California Parlor
7:00 AM–6:00 PM	One-on-One Partnering Desk Open	Sunset Court
7:00 AM–6:00 PM	Speaker Ready-Room Open	Mendocino
7:30 AM–8:25 AM	Networking Breakfast	Sunset Court
8:00 AM–11:55 AM	One-on-One Partnering Meetings	2 nd Floor
8:30 AM–11:55 AM	Discovery Track Presentations	Marina
8:30 AM–11:55 AM	Company Presentations	Pacific Heights, Presidio, Sea Cliff

Tuesday, October 25

9:00 AM–9:55 AM

BUSINESS ROUNDTABLES

FINANCING

Twin Peaks North/South

Dreaming of Public Exits-If not Now, then When...and How?

MODERATOR: David Parrot, Managing Director, BMO Capital Markets

- PANELISTS:
- Alan H. Auerbach, President & Chief Executive Officer, Puma Biotechnology, Inc.
 - Paul J. Hastings, President & Chief Executive Officer, OncoMed Pharmaceuticals, Inc.
 - Jonathan MacQuitty, PhD, Partner, Abingworth

The latest IPO window has stalled and global macro events threaten to completely shut it. Meanwhile, reverse mergers in Biotech continue to gain momentum with eight transactions in the last year alone. As chilly winds continue to blow through the latest IPO window, more private companies are considering this option among others. This panel will examine the current financing environment and common hurdles private executive teams need to be aware of as they pursue the public path.

Tuesday, October 25

10:30 AM–11:25 AM

THERAPEUTIC WORKSHOP

Twin Peaks North/South

IMMUNOTHERAPY

Heal Thyself

MODERATOR: Jason Kantor, PhD, Managing Director, RBC Capital Markets

- PANELISTS:**
- Hervé Brailly, PhD, Chief Executive Officer, Innate Pharma SA
 - Kevin Heller, MD, Director, Immuno-Oncology- Strategic Transactions Group, Bristol-Myers Squibb Company
 - Carlos Paya, MD, PhD, President & CEO, Immune Design Corp.
 - Timothy C. Rodell, MD, President & CEO, Globelimmune, Inc.

Enhancing the human body’s natural immune system to stimulate response and produce effective treatments has long been thought to be a promising approach to fighting cancer and other debilitating illnesses. However, until a couple of recent FDA approvals, there had been limited evidence of success with these types of treatments. By leveraging the body’s own ability to fight disease, immunotherapeutics effectively “work smarter” than traditional treatments. With pharma companies willing to pay top dollar to develop these drugs, the field of immunotherapy has piqued the interest of investors as well. Hear experts from companies at the forefront of this exciting field discuss what lies ahead.

Tuesday, October 25

12:00 PM–12:55 PM Box Lunches Available

Sunset Court

Tuesday, October 25

12:30 PM–1:25 PM

OPENING PLENARY SESSION

Twin Peaks North/South

The New Drug-Centric VC Universe—Return of the ROI

MODERATOR: David Strupp, Managing Director of Life Sciences and Healthcare Investment Banking Group, Rodman & Renshaw, LLC

- PANELISTS:**
- David Collier, Velocity Pharmaceutical Development
 - Sanjay Shukla, Chief Executive Officer, RxMed

As fewer biotechs are able to navigate successful exits, demand for new business models to bring back ROI is high. Investors are seeking faster paths to liquidity, and companies are eager to secure reliable streams of capital. A few agile VCs and entrepreneurs have radically innovated the traditional funding model to again make private biotech companies attractive investments. Whether constructing licensing deals where VCs receive cash dividends or rethinking corporate structure, these game-changing ventures focus on the drug, not on the company. This panel will explore these emerging deal and company structures, as well as innovative approaches to reengineering the biotech drug development model.

Tuesday, October 25

1:30 PM–4:55 PM	Company Presentations	Pacific Heights, Presidio Sea Cliff
1:30 PM–4:55 PM	Discovery Track and Private Company Presentations	Marina
1:30 PM–4:55 PM	One-on-One Partnering Meetings	2 nd Floor

Tuesday, October 25

2:00 PM–2:55 PM

THERAPEUTIC WORKSHOP

Twin Peaks North/South

BIOLOGICS

Billions for BioBetter?

MODERATOR: TBD

- PANELISTS:
- Douglas B. Neely, CMPE, MHA, Senior Director, Oncology Market Insights, Xcenda
 - William J. Newell, Chief Executive Officer, Sutro Biopharma, Inc.
 - Dee Athwal, fourteen22, Inc.

With patent expirations looming, pharma, large and small biotech are scrambling for “the next big thing.” An approval pathway for biosimilars is underway, with guidance from the Agency anticipated soon. What are the opportunities for new competitive products and even blockbusters? The question is who and with what technology? In the ultra-competitive space of biosimilars, selling a market clone may not be enough and will some companies seek to develop a biobetter or biosuperior? Panelists will differentiate products on the horizon and outline winning strategies for market penetration.

Tuesday, October 25

3:30 PM–4:25 PM

THERAPEUTIC WORKSHOP ANTIBODY DRUG CONJUGATES

Twin Peaks North/South

Beyond the ABCs of ADCs

MODERATOR: Michael G. King, Jr., Managing Director, Rodman & Renshaw LLC

- PANELISTS:**
- Mark R. Baker, Chief Executive Officer, Progenics Pharmaceuticals, Inc.
 - C. Geoffrey Davis, PhD, Chief Executive Officer, Angelica Therapeutics, Inc.
 - Jonathan Drachman, MD, Senior Vice President, Research and Translational Medicine, Seattle Genetics, Inc.
 - Juan Harrison, Vice President, Takeda Ventures
 - Timothy B. Lowinger, PhD, Chief Scientific Officer, Mersana Therapeutics, Inc.

The recent FDA approval of Seattle Genetics' antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC) leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won't be flickering anytime soon. Regulatory hurdles remain an issue, but is the biggest concern CMC or achieving a successful phase 3 program? How do different cancers respond to the ADC approach? Are we limited to chemotoxins in the pipeline today, or are there others on the horizon? Experts in this specialized antibody field will convene to discuss the latest developments and lessons of bringing ADCs through the clinic.

Tuesday, October 25

5:00 PM–7:00 PM

BIO Investor Forum Reception

Garden Court

Wednesday, October 26

6:30 AM–4:30 PM	Registration Open	California Parlor
6:30 AM–5:30 PM	Speaker Ready-Room Open	Mendocino
7:00 AM–3:30PM	One-on-One Partnering Desk Open	Sunset Court
7:00 AM–3:30 PM	One-on-One Partnering Meetings	2 nd Floor
7:30 AM–8:25 AM	Networking Breakfast	Sunset Court
8:30 AM–11:55 AM	Company Presentations	Pacific Heights, Presidio, Sea Cliff

Wednesday, October 26

9:00 AM–9:55 AM

BUSINESS ROUNDTABLES

Twin Peaks North/South

BUSINESS DEVELOPMENT

Broad is Beautiful—Multiple Assets Diversify the Deal

MODERATOR: TBD

- PANELISTS:
- Christine Grygon, PhD, Venture Capital Liaison/BI Partnering, Boehringer Ingelheim
 - Michael Margolis, RPh, Managing Director, ROTH Capital Partners
 - Steven E. Hall, PhD, Venture Partner, Lilly Ventures
 - Ali Tehrani, PhD, President & CEO, Zymeworks Inc.
 - Andrew Merickel, PhD, Partner, Knobbe, Martens, Olson & Bear, LLP

With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery-stage partnering deals seem to be the “BD deal du jour.” Striking a discovery-stage deal can be extremely beneficial for both parties in today’s environment. Pharma gets to fill its ever elusive R&D pipeline as patent expirations loom, and the small biotech struggling to raise money to stay alive gets the capital infusion necessary to stay in play. De-risking has become a theme for deal-making in a difficult market environment. Is the best strategy to cast a wide net and diversify as much as possible? Are the days of straightforward single-asset deals a thing of the past? Company executives on both sides of the table of recent discovery deals will convene to provide their insights on their experiences.

Wednesday, October 26

10:30 AM–11:25 AM

THERAPEUTIC WORKSHOP

Twin Peaks North/South

DIAGNOSTICS

X Marks the Spot—Companion Dx in Oncology

MODERATOR: Scott Allocco, President and Co-founder, BioMarker Strategies

- PANELISTS:**
- Steven M. Anderson, PhD, Chief Scientific Officer of Oncology and Genetics, LabCorp and Monogram Biosciences
 - Rollie Carlson, PhD, President, Asuragen, Inc.
 - Alan Wahl, Senior Director Oncology, Global Pharmaceutical Research & Development, Abbott

Insights into the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions among validated patient populations. Promising improved treatment outcomes tailored to genetic etiology and disease pathology, the field of companion diagnostics not only ignites the interest of clinicians and investors, but is also spurs potentially lucrative industry partnerships. Focusing on these new markets, industry executives and investors will guide a discussion of some of the most compelling new technologies and applications for companion diagnostics in oncology.

Wednesday, October 26

12:00 PM–12:55 PM Box Lunches Available

Sunset Court

Wednesday, October 26
12:00 pm–12:55 pm

LUNCHEON PLENARY

Twin Peaks North/South

Corporate Venture Funds and Traditional VCs: Can They Coexist?

MODERATOR: Jeron Eaves, Practice Executive, Campbell Alliance

- PANELISTS:**
- Brian G. Atwood, Managing Director, Versant Ventures
 - Brian McVeigh, Vice-President, Worldwide Business Development Transactions, GlaxoSmithKline
 - Janis Naeve, PhD, Director, Amgen Ventures
 - Asish K. Xavier, PhD, Vice President, Johnson & Johnson Development Corporation

Many traditional VC firms were forced to do some “soul searching” on their business model during the last market downturn. They shifted to the early, most innovative and transformational start-ups, shying away from lingering projects in competitive markets. During the same period, corporate venture funds began to step up to fill critical financing gaps for these early stage start-ups, and we’ve steadily seen an increase in the number of large companies with their own funds. In today’s competitive licensing environment for early-stage assets and with traditional venture capital financing on the rebound, a question remains: How best can corporate venture funds and traditional VCs coexist? Please join our panel of corporate and traditional venture capitalists as they discuss their financing strategies and areas of focus, as well as the opportunities and challenges associated with bringing the next series of innovative products to market.

Wednesday, October 26

1:00 PM–3:25 PM

Discovery Track/Company Presentations

Marina, Pacific Heights,
 Presidio, Sea Cliff

Wednesday, October 26

1:30 PM–2:25 PM

THERAPEUTIC WORKSHOP

Twin Peaks North/South

INFECTIOUS DISEASE

Resistance is Futile—SuperDrugs for SuperBugs

MODERATOR: Susan Schaeffer, Senior Editor, BioCentury Publications

- PANELISTS:**
- Brian R. Dixon, PhD, President & CEO, BioRelix, Inc.
 - Mark Leuchtenberger, President & CEO, Rib-X Pharmaceuticals, Inc.
 - David P. Perry, Chief Executive Officer, Anacor Pharmaceuticals, Inc.
 - Jeffrey Stein, PhD, President & CEO, Trius Therapeutics, Inc.

While new superbugs are on the rise, new superdrugs to combat these remain few and far-between. The incidence of both gram negative and gram positive antibiotic drug resistance continues to increase, and innovative drugs with novel mechanisms of action are sorely needed in the antibiotic pipeline. With large pharma increasingly exiting the antibacterial drug discovery market, the space is ripe for small biotech to fill the void. Hear the companies riding the next wave of antibiotic drug discovery discuss the opportunities and challenges of this ever-evolving field.

Wednesday, October 26

3:30 PM–4:25 PM

CLOSING PLENARY SESSION

Twin Peaks North/South

Opportunity or Apocalypse? Prophecies for 2012

MODERATOR: Luke Timmerman, National Biotech Editor, Xconomy

- PANELISTS:**
- Ron Laufer, MD, Senior Managing Director, MedImmune Ventures
 - Matthew D. Perry, Portfolio Manager, Biotechnology Value Fund, LP (BVF)
 - Bryan Roberts, PhD, Partner, Venrock
 - Kurt von Emster, PhD, Managing Director, venBio LLC

Is 2012 the end of the world as we know it? Or is this prediction just bunk? How will the industry fare with the still volatile market conditions? Will world economies affect the ability for companies to acquire financing? Join seasoned biotech investors for a candid and insightful discussion on what we can expect in 2012.

Wednesday, October 26

4:30 PM–5:45 PM

Closing Happy Hour

Sunset Court

Presenting Companies

Alphabetical Listing of Presenting Companies 16

Categorical Listing of Presenting Companies..... 19

*Current as of Thursday, October 13, 2011. Schedule subject to change.
Please see final daily schedules posted in the corridors.*

*Discovery Track company presentations are 15 minutes long,
including a Q&A session in the same room.*

*Public and private company presentations are 20 minutes long
and will be followed by a 5-minute Q&A session in the same room.*

A Decade of Excellence

THE 10TH ANNUAL

Bio ***Investor Forum***

ALPHABETICAL LISTING PRESENTING COMPANIES

Company (TICKER)	Clinical Focus	Ownership	Location
13therapeutics, Inc.	Autoimmune/Inflammation	Discovery	OR – USA
A&G Pharmaceutical, Inc.	Oncology	Discovery	MD – USA
Aciont Inc.	Ophthalmology	Discovery	UT – USA
Addex Pharmaceuticals SA (SWF-ADNX)	CNS	Public	CHE
Advaxis Inc. (ADXS)	Oncology	Public	NJ – USA
ADVENTRX Pharmaceuticals, Inc. (ANX)	Oncology	Public	CA – USA
Aegerion Pharmaceuticals, Inc. (AEGR)	Metabolic Diseases	Public	MA – USA
Aeolus Pharmaceuticals, Inc. (AOLS)	CNS	Public	CA – USA
Afraxis, Inc.	CNS	Discovery	CA – USA
Akebia Therapeutics, Inc.	Cardiology	Private	OH – USA
Allon Therapeutics Inc. (TSE: NPC)	CNS	Public	BC – CAN
Anacor Pharmaceuticals, Inc. (ANAC)	Infectious Diseases	Public	CA – USA
Anaphore, Inc.	Autoimmune/Inflammation	Private	CA – USA
Anchor Therapeutics, Inc.	Oncology	Private	MA – USA
Ancora Pharmaceuticals Inc.	Vaccines	Private	MA – USA
Aquinox Pharmaceuticals Inc.	Autoimmune/Inflammation	Private	BC – CAN
Aradigm Corporation (ARDM)	Respiratory	Public	CA – USA
Arbovax, Inc.	Vaccines	Discovery	NC – USA
ASLAN Pharmaceuticals Pte. Ltd.	Oncology	Private	SGP
Astex Pharmaceuticals, Inc. (ASTX)	Oncology	Public	CA – USA
Auspex Pharmaceuticals, Inc.	CNS	Private	CA – USA
Axikin Pharmaceuticals, Inc.	Autoimmune/Inflammation	Discovery	CA – USA
Bio-Path Holdings, Inc. (BPTH)	Oncology	Public	TX – USA
BioSante Pharmaceuticals, Inc. (BPAX)	Hormone Therapy	Public	IL – USA
Catabasis Pharmaceuticals, Inc.	Metabolic Diseases	Private	MA – USA
Catalyst Pharmaceutical Partners, Inc. (CPRX)	CNS	Public	FL – USA
Cell Therapeutics, Inc. (CTIC)	Oncology	Public	WA – USA
CoMentis, Inc.	CNS	Private	CA – USA
Constellation Pharmaceuticals, Inc.	Oncology	Private	MA – USA
CureFAKtor Pharmaceuticals, LLC	Oncology	Discovery	NY – USA
Curis Inc. (CRIS)	Oncology	Public	MA – USA
Cyclacel Pharmaceuticals, Inc. (CYCC)	Oncology	Public	NJ – USA
Cyterix Pharmaceuticals, Inc.	Oncology	Discovery	CA – USA
Del Mar Pharmaceuticals Inc.	Oncology	Discovery	BC – CAN
Dicerna Pharmaceuticals, Inc.	Autoimmune/Inflammation	Private	MA – USA
DLVR Therapeutics Inc.	Oncology	Discovery	ON – CAN
DNA Therapeutics SA	Oncology	Discovery	FRA
Elusys Therapeutics, Inc.	Infectious Diseases	Private	NJ – USA
Envoy Therapeutics, Inc.	CNS	Discovery	FL – USA
Epiomed Therapeutics, Inc.	CNS	Discovery	CA – USA
Epizyme, Inc.	Oncology	Private	MA – USA
Esperion Therapeutics, Inc.	Cardiology	Discovery	MI – USA
FasterCures*	Patient Advocacy Group	PAG	USA
Flexion Therapeutics, Inc.	Autoimmune/Inflammation	Private	MA – USA
FluGen, Inc.	Infectious Diseases	Discovery	WI – USA
Galena Biopharma, Inc. (formerly RXI Pharmaceuticals) (RXII)	Oncology	Public	MA – USA
Gamma Therapeutics, Inc.	Diagnostics	Discovery	OR – USA
GATEKEEPER Pharmaceuticals, Inc.	Oncology	Private	CA – USA
Genocea Biosciences, Inc.	Infectious Diseases	Private	MA – USA
Genprex, Inc.	Oncology	Discovery	TX – USA
GenVec, Inc. (GNVC)	Vaccines	Public	MD – USA

*Patient Advocacy Group/Venture Philanthropy

ALPHABETICAL LISTING PRESENTING COMPANIES

Company (TICKER)	Clinical Focus	Ownership	Location
GlobelImmune Inc.	Oncology	Private	CO – USA
GlycoRegImmune, Inc.	Autoimmune/Inflammation	Discovery	CA – USA
G-Zero Therapeutics, Inc.	Oncology	Discovery	CA – USA
HemaQuest Pharmaceuticals, Inc.	Hematology	Private	CA – USA
Heptares Therapeutics Limited	CNS	Private	UK
Ikaria, Inc.	Drug Delivery	Private	NJ – USA
Immune Design Corp.	Infectious Diseases	Private	WA – USA
Immune Targeting Systems Ltd.	Infectious Diseases	Discovery	UK
ImmunoCellular Therapeutics, Ltd. (IMUC)	Oncology	Public	CA – USA
ImmunoGenes AG	Platform	Discovery	HUN
ImmusanT, Inc.	Autoimmune/Inflammation	Discovery	MA – USA
Indel Therapeutics Inc.	Infectious Diseases	Discovery	BC – CAN
Inimex Pharmaceuticals Inc.	Infectious Diseases	Private	BC – CAN
Innate Pharma SA (EPA:IPH)	Oncology	Public	FRA
Intra-Cellular Therapies, Inc.	CNS	Private	NY – USA
InVasc Therapeutics, Inc.	Cardiology	Discovery	GA – USA
Jennerex Biotherapeutics, Inc.	Oncology	Private	CA – USA
Kalos Therapeutics, Inc.	Oncology	Discovery	CA – USA
Kareus Therapeutics, SA	CNS	Discovery	CHE
LigoCyte Pharmaceuticals, Inc.	Vaccines	Private	MT – USA
Lipocine Inc.	Hormone Therapy	Private	UT – USA
MabVax Therapeutics, Inc.	Vaccines	Private	CA – USA
MaxCyte, Inc.	Oncology	Private	MD – USA
MDA Venture Philanthropy*	Patient Advocacy Group	PAG	USA
Mersana Therapeutics, Inc.	Oncology	Private	MA – USA
MetaSignal Therapeutics Inc.	Oncology	Discovery	BC – CAN
Mirna Therapeutics Inc.	Oncology	Private	TX – USA
Mithridion, Inc.	CNS	Private	WI – USA
Molecular Templates Inc.	Gene/Cell Therapy	Discovery	TX – USA
NanoCarrier Co., Ltd. (TYO:4571)	Platform	Public	JPN
P2D Bioscience, Inc.	CNS	Discovery	OH – USA
Palatin Technologies, Inc. (PTN)	Metabolic Diseases	Public	NJ – USA
PharmaNeuroBoost NV	CNS	Discovery	BEL
PLx Pharma Inc.	Cardiology	Private	TX – USA
ProNAi Therapeutics, Inc.	Oncology	Private	MI – USA
Prosensa Therapeutics BV	Genetic Diseases	Private	NLD
Protagonist Therapeutics, Inc.	Platform	Discovery	CA – USA
Provectus Pharmaceuticals, Inc. (PVCT)	Oncology	Public	TN – USA
Relypsa, Inc.	Metabolic Diseases	Private	CA – USA
Resverlogix Corp. (TSE:RVX)	Cardiology	Public	AB – CAN
Rib-X Pharmaceuticals, Inc.	Infectious Diseases	Private	CT – USA
Savara Inc.	Drug Delivery	Private	TX – USA
Senesco Technologies, Inc. (SNT)	Gene/Cell Therapy	Public	NJ – USA
Sirius Genomics Inc.	Diagnostics	Discovery	BC – CAN
Sorbent Therapeutics, Inc.	Drug Delivery	Private	CA – USA
Spinifex Pharmaceuticals Pty. Ltd.	CNS	Private	AUS
STATegics, Inc.	CNS	Discovery	CA – USA
SuperNova Diagnostics, Inc.	Diagnostics	Discovery	MD – USA
SuppreMol GmbH	Autoimmune/Inflammation	Private	DEU
Syndax Pharmaceuticals, Inc.	Oncology	Private	MA – USA
SynTara LLC	Oncology	Discovery	USA

**Patient Advocacy Group/Venture Philanthropy*

ALPHABETICAL LISTING PRESENTING COMPANIES

Company (TICKER)	Clinical Focus	Ownership	Location
Syntaxin Ltd.	Oncology	Private	UK – UK
TESARO	Oncology	Private	MA – USA
Tetraphase Pharmaceuticals, Inc.	Infectious Diseases	Private	MA – USA
Tobira Therapeutics, Inc.	Infectious Diseases	Private	NJ – USA
Tranzyme Inc. (TZYM)	Gastroenterology	Public	NC – USA
Trevena Inc.	CNS	Private	PA – USA
Trius Therapeutics, Inc. (TSRX)	Infectious Diseases	Public	CA – USA
Unigene Laboratories, Inc. (UGNE)	Metabolic Diseases	Public	NJ – USA
XOMA LLC (XOMA)	Autoimmune/Inflammation	Public	CA – USA
Zalicus Inc. (ZLCS)	CNS	Public	MA – USA
ZIOPHARM Oncology Inc. (ZIOP)	Oncology	Public	NY – USA
Zymeworks Inc.	Platform	Private	BC – CAN

CATEGORICAL LISTING PRESENTING COMPANIES

Autoimmune/Inflammation

13therapeutics, Inc.	Discovery	OR – USA
Anaphore, Inc.	Private	CA – USA
Aquinox Pharmaceuticals Inc.	Private	BC – CAN
Axikin Pharmaceuticals, Inc.	Discovery	CA – USA
Dicerna Pharmaceuticals, Inc.	Private	MA – USA
Flexion Therapeutics, Inc.	Private	MA – USA
GlycoRegImmune, Inc.	Discovery	CA – USA
ImmusanT, Inc.	Discovery	MA – USA
SuppreMol GmbH	Private	DEU
XOMA LLC (XOMA)	Public	CA – USA

Cardiology

Akebia Therapeutics, Inc.	Private	OH – USA
Esperion Therapeutics, Inc.	Discovery	MI – USA
InVasc Therapeutics, Inc.	Discovery	GA – USA
PLx Pharma Inc.	Private	TX – USA
Resverlogix Corp. (TSE:RVX)	Public	AB – CAN

CNS

Addex Pharmaceuticals SA (SWF:ADXN)	Public	CHE
Aeolus Pharmaceuticals, Inc. (AOLS)	Public	CA – USA
Afraxis, Inc.	Discovery	CA – USA
Allon Therapeutics Inc. (TSE:NPC)	Public	BC – CAN
Auspex Pharmaceuticals, Inc.	Private	CA – USA
Catalyst Pharmaceutical Partners, Inc. (CPRX)	Public	FL – USA
CoMentis, Inc.	Private	CA – USA
Envoy Therapeutics, Inc.	Discovery	FL – USA
Epiomed Therapeutics, Inc.	Discovery	CA – USA
Heptares Therapeutics Limited	Private	UK
Intra-Cellular Therapies, Inc.	Private	NY – USA
Kareus Therapeutics, SA	Discovery	CHE
Mithridion, Inc.	Private	WI – USA
P2D Bioscience, Inc.	Discovery	OH – USA
PharmaNeuroBoost NV	Discovery	BEL
Spinifex Pharmaceuticals Pty. Ltd.	Private	AUS
STATegics, Inc.	Discovery	CA – USA
Trevena Inc.	Private	PA – USA
Zalicus Inc. (ZLCS)	Public	MA – USA

Diagnostics

Gamma Therapeutics, Inc.	Discovery	OR – USA
Sirius Genomics Inc.	Discovery	BC – CAN
SuperNova Diagnostics, Inc.	Discovery	MD – USA

Drug Delivery

Ikaria, Inc.	Private	NJ – USA
Savara Inc.	Private	TX – USA
Sorbent Therapeutics, Inc.	Private	CA – USA

CATEGORICAL LISTING PRESENTING COMPANIES

Gastroenterology

Tranzyme Inc. (TZYM)	Public	NC – USA
----------------------	--------	----------

Gene/Cell Therapy

Molecular Templates Inc.	Discovery	TX – USA
Senesco Technologies, Inc. (SNT)	Public	NJ – USA
Prosensa Therapeutics BV	Private	NLD

Hematology

HemaQuest Pharmaceuticals, Inc.	Private	CA – USA
---------------------------------	---------	----------

Hormone Therapy

BioSante Pharmaceuticals, Inc. (BPAX)	Public	IL – USA
Lipocine Inc.	Private	UT – USA

Infectious Diseases

Anacor Pharmaceuticals, Inc. (ANAC)	Public	CA – USA
Elusys Therapeutics, Inc.	Private	NJ – USA
FluGen, Inc.	Discovery	WI – USA
Genocea Biosciences, Inc.	Private	MA – USA
Immune Design Corp.	Private	WA – USA
Immune Targeting Systems Ltd.	Discovery	UK
Indel Therapeutics Inc.	Discovery	BC – CAN
Inimex Pharmaceuticals Inc.	Private	BC – CAN
Rib-X Pharmaceuticals, Inc.	Private	CT – USA
Tetraphase Pharmaceuticals, Inc.	Private	MA – USA
Tobira Therapeutics, Inc.	Private	NJ – USA
Trius Therapeutics, Inc. (TSRX)	Public	CA – USA

Metabolic Diseases

Aegerion Pharmaceuticals, Inc. (AEGR)	Public	MA – USA
Catabasis Pharmaceuticals, Inc.	Private	MA – USA
Palatin Technologies, Inc. (PTN)	Public	NJ – USA
Relypsa, Inc.	Private	CA – USA
Unigene Laboratories, Inc. (UGNE)	Public	NJ – USA

Oncology

A&G Pharmaceutical, Inc.	Discovery	MD – USA
Advaxis Inc. (ADXS)	Public	NJ – USA
ADVENTRX Pharmaceuticals, Inc. (ANX)	Public	CA – USA
Anchor Therapeutics, Inc.	Private	MA – USA
ASLAN Pharmaceuticals Pte. Ltd.	Private	SGP
Astex Pharmaceuticals, Inc. (ASTX)	Public	CA – USA
Bio-Path Holdings, Inc. (BPTH)	Public	TX – USA
Cell Therapeutics, Inc. (CTIC)	Public	WA – USA
Constellation Pharmaceuticals, Inc.	Private	MA – USA
CureFAKTor Pharmaceuticals, LLC	Discovery	NY – USA
Curis Inc. (CRIS)	Public	MA – USA
Cyclacel Pharmaceuticals, Inc. (CYCC)	Public	NJ – USA
Cyterix Pharmaceuticals, Inc.	Discovery	CA – USA

Oncology (continued)

Del Mar Pharmaceuticals Inc.	Discovery	BC – CAN
DLVR Therapeutics Inc.	Discovery	ON – CAN
DNA Therapeutics SA	Discovery	FRA
Epizyme, Inc.	Private	MA – USA
Galena Biopharma, Inc. (formerly RXi Pharmaceuticals) (RXII)	Public	MA – USA
GATEKEEPER Pharmaceuticals, Inc.	Private	CA – USA
Genprex, Inc.	Discovery	TX – USA
GlobelImmune Inc.	Private	CO – USA
G-Zero Therapeutics, Inc.	Discovery	CA – USA
ImmunoCellular Therapeutics, Ltd. (IMUC)	Public	CA – USA
Innate Pharma SA (EPA:IPH)	Public	FRA
Jennerex Biotherapeutics, Inc.	Private	CA – USA
Kalos Therapeutics, Inc.	Discovery	CA – USA
MaxCyte, Inc.	Private	MD – USA
Mersana Therapeutics, Inc.	Private	MA – USA
MetaSignal Therapeutics Inc.	Discovery	BC – CAN
Mirna Therapeutics Inc.	Private	TX – USA
ProNAi Therapeutics, Inc.	Private	MI – USA
Provectus Pharmaceuticals, Inc. (PVCT)	Public	TN – USA
Syndax Pharmaceuticals, Inc.	Private	MA – USA
SynTara LLC	Discovery	USA
Syntaxin Ltd.	Private	UK – UK
TESARO	Private	MA – USA
ZIOPHARM Oncology Inc. (ZIOP)	Public	NY – USA

Ophthalmology

Aciont Inc.	Discovery	UT – USA
-------------	-----------	----------

Patient Advocacy Groups

FasterCures	PAG	USA
MDA Venture Philanthropy	PAG	USA

Platform

ImmunoGenes AG	Discovery	HUN
NanoCarrier Co., Ltd. (TYO:4571)	Public	JPN
Protagonist Therapeutics, Inc.	Discovery	CA – USA
Zymeworks Inc.	Private	BC – CAN

Respiratory

Aradigm Corporation (ARDM)	Public	CA – USA
----------------------------	--------	----------


*Patient Advocacy Group/Venture Philanthropy

CATEGORICAL LISTING PRESENTING COMPANIES

Vaccines

Ancora Pharmaceuticals Inc.	Private	MA – USA
Arbovax, Inc.	Discovery	NC – USA
GenVec, Inc. (GNVC)	Public	MD – USA
LigoCyte Pharmaceuticals, Inc.	Private	MT – USA
MabVax Therapeutics, Inc.	Private	CA – USA

Palace Hotel Second Floor



UPCOMING BIO EVENTS

17th Annual Bio-Europe® International Partnering Conference

October 31–November 2, 2011 | Düsseldorf, Germany

9th Annual BIO Asia International Partnering Conference

January 31–February 1, 2012* | Osaka, Japan

14th Annual Bio CEO & Investor Conference

February 13–14, 2012 | New York, New York

BIO Europe Spring

March 19–21, 2012 | Amsterdam, Holland

BioEquity Europe 2012

May 15–16, 2012 | Frankfurt, Germany

BIO-LES Business Development Basics Course

June 16–18, 2012, Boston, Massachusetts

BIO-LES Advanced Business Development Course

June 16, 2012 | Boston, Massachusetts

The Business Forum at the BIO International Convention

June 18–21, 2012 | Boston, Massachusetts

3rd Annual BIO India International Conference

September 2012* | India

The BIO International Convention in China

October 2012* | Shanghai

*Specific dates to be announced.